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COMMENTARY
Myocardial infarction:
ACE inhibitors for all? for ever?
The beneficial, life-saving effect of angiotensin converting
enzyme (ACE) inhibition in patients with signs of
impaired cardiac function early after myocardial infarction
was shown by the AIRE study.’ At an average follow-up
of 15 months, mortality was 23% in 982 patients in the
placebo group vs 17% in 1004 patients in the ramipril
group. In this study ramipril was started between 3 and
10 days after infarction. More recently GISSI-32 showed
that treatment with an ACE inhibitor immediately after
hospital admission was beneficial when given to all
patients with myocardial infarction. In GISSI-3, mortality
at 6 weeks was 7-1% in 9460 open controls vs 6-3% in
9435 patients receiving oral lisinopril. These observations
are supported by preliminary data from ISIS-4, which has
been reported,3 but not yet published, but contrast with
the absence of any mortality benefit in patients treated
with intravenous and oral enalapril in the 6090 patients in
the CONSENSUS-11 study.
So, should all patients with myocardial infarction
receive an ACE inhibitor immediately, or should such
therapy be initiated later in selected patients? To resolve
this question several issues have to be addressed,
including the pathophysiology of ACE inhibition during
and after myocardial infarction and the differences
between the trials. In any event, treatment with an ACE-
inhibitor, once started in patients with heart failure or left
ventricular dysfunction, should be continued indefinitely
since long-term beneficial effects from such therapy have
been shown in several large trials
Survival after myocardial infarction is determined
predominantly by residual left ventricular function,’ which
is the result of three distinct but overlapping
pathophysiological processes: (a) the initial loss of
myocytes (infarct size); (b) subsequent stretching and
thinning of the infarcted segment during the first few days
(infarct expansion), and (c) further remodelling of both
infarcted and non-infarcted myocardium over several
months.
Attenuation of the ischaemic insult by captopril was
observed in a pig model of coronary occlusion and
reperfusion.9 By comparison with saline, release of
creatine kinase, inosine, and noradrenaline was reduced
by the ACE inhibitor. In a rat model captopril, but not
enalapril, reduced ventricular fibrillation upon
reperfusion.11 In another rat model," captopril during
1-21 days after coronary artery ligation did not reduce
infarct size, whereas enalapril has been observed to limit
infarct size in rats. In a study in which infarct size was
measured by serial enzyme determinations in 298 patients
with a first anterior infarction treated with streptokinase
and either captopril or placebo,’3 a 15% limitation of size
was reported in those with a large infarct, but differences
in the whole group were not statistically significant.
Moreover, left ventricular ejection fraction after 3 months
was the same (44%) in the placebo and captopril groups.
ACE inhibitors have strong neurohumoral effects: apart
from suppressing plasma angiotensin converting enzyme
activity, they lower plasma noradrenaline and increase
plasma renin activity in patients with myocardial
infarction."’’" Systemic blood pressure is reduced with the
first dose,13 but the effect on infarct size in clinical practice
is uncertain. Unfortunately measurement of infarct size
was not included in some of the patients in
CONSENSUS-11 and GISSI-3.
All studies in which echocardiography or
ventriculography was used point to the preservation of left
ventricular function by ACE inhibition in patients with
large infarcts.11 ...... Nevertheless, most series were small
and the data were often not significant within the
study."’’" Several groups have analysed the time-course of
global and regional left ventricular function, showing that
both infarct expansion and remodelling can be attenuated
by ACE inhibitors. For example, in the Glaswegian
study," there was a significant increase in the length of
the infarct-related left ventricular segment after 2 months
in the placebo group, with smaller changes after captopril.
About half this effect was already apparent at day 3 and
day 7. Similarly beneficial effects of captopril on left
ventricular end-diastolic volume, end-systolic volume,
and ejection fraction were apparent after 7 days in a New
Zealand study.’8
One way to examine the different outcomes of GISSI-3
and CONSENSUS-II would be a statistical approach-
combination of all mortality data of these studies and of
ISIS-4 and the smaller studies in a single analysis. In such
an analysis, GISSI-3 and ISIS-4 would dominate and
there would be an overall beneficial effect of immediate
ACE inhibition in all patients with evolving infarction.
However, this strategy does not really explain the
differences between trials, and physicians who want to
select the best treatment for individual patients are bound
to remain bewildered.
There are important differences between the studies as
shown in the table. In CONSENSUS-II there were more
elderly patients, fewer women, and more patients with a
previous infarction. In GISSI-3 more patients were
treated within 12 hours of symptom onset, and more
patients received thrombolytic therapy. Few data on
specific patient subgroups have been presented, so we do
not know whether these differences can explain the
differences in outcome between the two trials. In
CONSENSUS-11 there was some excess mortality in
elderly patients receiving enalapril, but this was not
confirmed in GISSI-3.
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*Infarct site reported for all patients in CONSENSUS-II and in those with Q-waves only
in GISSI-3.
tCONSENSUS-1I reported mean values and GISSI-3 the distribution in certain ranges; in
the table the range including the median value is presented.
*Any beta-blockers before randomisation (CONSENSUS-II) or intravenous beta-blockers
only (GISSI-3).
Table: Comparison of selected baseline characteristics in two
trials of immediate ACE inhibition in myocardial infarction
Different ACE inhibitors were studied-enalapril in
CONSENSUS-II and lisinopril in GISSI-3- but I am
not aware of pharmacological differences between these
two drugs that could explain different outcomes. Both
drugs have a plasma half-life of about 12 hours. However,
the mode of administration differed considerably.
Enalapril was initiated with a 2-hour intravenous infusion
followed by ascending oral dosing; most patients (82%)
reached the target dose of 20 mg/day on day 10.
Lisinopril was given orally and only 48% of patients
received the full dose of 10 mg/day. The more rapid
intravenous administration of enalapril resulted more
frequently in hypotension: 12% in CONSENSUS-II vs
9% in GISSI-3 with blood pressure less than 90 mm Hg.
This fall in pressure may have led to increased mortality
in CONSENSUS-11, as has already been suggested by the
investigators4 and this might have offset a potential
beneficial effect of the drug.
Immediate intravenous administration of an ACE
inhibitor carries a risk for hypotension, especially if the
drug is given in combination with streptokinase.2’
However, such immediate administration would be
warranted if it resulted in myocardial salvage. Since
limitation of infarct size has not been shown
unequivocally, it seems prudent to avoid immediate ACE
inhibition for the time being.
Improved survival with ACE inhibition in patients with
myocardial infarction seems to be due to attenuation of
infarct expansion and remodelling. Accordingly,
treatment will be most effective in patients at risk for such
changes, during the period at which these processes
evolve. Thus treatment in appropriate patients should be
started early-within a few days, but not necessary
immediately after hospital admission.
If a decision has been made to give an ACE inhibitor, a
low oral dose should be given first. Intravenous
administration seems unnecessary and possibly harmful.’
Once started, the therapy can be continued indefinitely,
unless side-effects or contraindications develop.
Patients at risk for significant infarct extension and
remodelling are those with larger infarcts, so it is logical to
select such patients for ACE-inhibition. The AIRE study
specifically selected patients with clinical signs of
impaired cardiac function and showed a 27% relative risk
reduction (absolute mortality benefit 6%). The smaller
(12% relative or 0-5% absolute) reduction in GISSI-3
might reflect a combination of a bigger effect in patients
with larger infarcts and heart failure and a smaller or no
effect in those with a small infarct. Indeed, GISSI-3
patients in Killip class 2 or greater had a 3% mortality
benefit vs only 0-3% in patients without heart failure
(Killip class 1) at admission .11,2’ Additional subgroup
analyses of GISSI-3, and possibly ISIS-4, are eagerly
awaited to assess which patients really benefit from early
ACE inhibition.
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Whither cancer centres?
The consultative document A Policy Framework for
Commissioning Cancer Services’ recommends the
establishment of a hierarchy of cancer centres and units in
each National Health Service (NHS) region in England
and Wales. Primary care is seen as the focus, and due
emphasis is paid to family and psychosocial issues. The
report anticipates intense communication and
coordination in support of the central theme-namely,
that geography should not be a determinant of the quality
of cancer treatment. By making these recommendations,
the report raises a fundamental issue about the concept of
cancer centres. Do such centres meet the need for cancer
control; if not, do we need them at all?
The evolution of both medical science and public
perception with respect to cancer has been so profound
that we tend to forget the original premises (apart from the
control of radium) upon which cancer centres were
established. 50 years ago the word cancer was enunciated
in hushed tones, and for most patients there was little that
could be done. Health professionals were uncomfortable
talking about cancer, and reticent to assume a substantive
treatment role. The few who did formed the small working
groups that evolved into the main cancer centres of mid-
century. Our predecessors knew little of aetiology or
epidemiology, and the focus was treatment of advanced
disease. Nevertheless, their efforts earned an almost saintly
public esteem, and established the political basis for major
public expenditures in cancer treatment and research.
Times have changed. We now understand cancer to be a
family of chronic diseases. Although there is a vast array of
treatments for most malignant disorders and
"breakthroughs" are reported daily, overall death rates
have not been much improved. There is public frustration
on several counts: lack of progress in treatment,
fragmentation of care, inequity of access, and apparent
politicisation of pain and suffering. To soothe the public
anger and meet the biological need, we need to look at
these issues from the broad perspective of cancer control.
The goal is to diminish mortality and morbidity and by so
doing augment quality of life. From a strategic perspective,
the future of cancer control, and of cancer centres,
depends on our understanding of its "spectrum"; a method
to diffuse effective techniques; and the establishment of a
pragmatic, efficient evaluation infrastructure.2
Cancer control is not treatment-it is prevention, early
diagnosis, treatment, and palliation. Each of these
elements is characterised by unique strategies for
implementation and evaluation. For example, prevention
requires a substantive understanding of aetiology, and its
evaluation is incidence-population based. By contrast,
palliation is case-centred, and effectiveness is measured
by the extent to which symptoms are relieved and quality
of life is restored. For each cancer we must target our
efforts for maximum effect. Our knowledge of aetiology
and the dearth of effective therapy suggests that we
should prevent lung cancer rather than emphasise
treatment. We should screen for cervical cancer. We
should treat lymphomas, childhood tumours, germ-cell
tumours, and within limited goals, the overwhelming
prevalence of epithelial tumours. From the perspectives of
both individual patient and social policy, we have to
understand the means and principles of palliation at all
stages of disease. Traditional cancer centres tend to focus
on treatment to the exclusion of other elements.
Diffusion of technology is the second perspective of
cancer control. We tend to think in institutional terms
rather than by jurisdiction. There is a tendency to
centralise new therapies out of concern for safety, cost,
and research priority. Yet if one quarter or more of the
population is destined to develop a treatable chronic
disease, free-standing cancer centres will either become
parallel health systems, which we cannot afford, or will
implode under the load, thereby compromising the
specialised insight and evaluation capacity that represents
their raison d’etre. Furthermore, the social dislocation
inherent in treating a chronic disease at a distant site can
be lessened by a distributed delivery system. The question
is how to maintain both research and treatment quality.
Three principles form the basis of a strategy. The first is
to distinguish that which needs to be centralised because
it is capital intensive (eg, linear accelerators) from that
which is conceptually complex but technologically simple
(eg, chemotherapy). The latter can be decentralised safely
provided there is adequate information and control. The
second principle is to consider the trajectory of an illness
as a predictable pathway punctuated by both planned and
unplanned decision points, at which multidisciplinary
specialist input is required. The third is to acknowledge
the skills of the cancer specialist team in the medical
aspects of the disease, and of the local physician in the
comorbidities and psychosocial dimensions. Our
experience over 15 years in Manitoba, Canada, convinces
us that community physicians, with expert monitoring
and support from a distance, can be trained to recognise
decision points, and in this way cancer chemotherapy and
follow-up can be safely decentralised.3
The essence of future cancer control is not solely a
treatment place, but also a jurisdictional information
infrastructure; a cancer programme. The key is to
establish evidence-based multidisciplinary approaches to
each tumour across the cancer spectrum. That means
facilitating and paying for experts with ongoing
experience to enable them to define and disseminate
practical guidelines, and to monitor implementation. It
means supporting research, and providing a distributed
substantive information infrastructure. There is no
